Ebronucimab vs Lerodalcibep
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
Lerodalcibep · Lerochol
Marketed by LIB Therapeutics and partners
NCT04797104 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.
Next expected readout: July 2028 · NCT07102511 (registry estimate)
Reported efficacy
Change from baseline compared to placebo in LDL-C level (24 weeks): LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) (met)
Result source: NCT04797104
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | Lerodalcibep |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | -53% vs -45.3%avs inclisiranNCT050046751 other result
|
| Non-HDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT04790513 |
| ApoB, % change | —Not posted · NCT05260411 | —Not posted · NCT04790513 |
| Lp(a), % change | —Not posted · NCT05260411 | —Not posted · NCT04790513 |
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Not posted · NCT04790513 |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Lerodalcibep
- -53% vs -45.3%avs inclisiranNCT05004675
1 other result
- -9.3% vs -11% NCT04034485
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Lerodalcibep
- —Not posted · NCT04790513
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- Lerodalcibep
- —Not posted · NCT04790513
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- Lerodalcibep
- —Not posted · NCT04790513
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- Lerodalcibep
- —Not posted · NCT04790513
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Ebronucimab: 1 of 5 rows · Lerodalcibep: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ebronucimab | Lerodalcibep |
|---|---|---|
| LDL-C percent change · % of baseline No placebo or comparator arm | -59.13% @ 12wk450 mg Q4Wa,b,c NCT05255094 · Phase 3 · sponsor-reported, not registry data show 1 more dose-60.43% @ 12wk150 mg Q2W NCT05255094 · Phase 3 · sponsor-reported, not registry data | 58.61% @ 24wka,b,c NCT04797104 · Phase 3 · sponsor-reported, not registry data show 1 more dose65% NCT04797104 · Phase 3 · sponsor-reported, not registry data |
| Dropout rate | — | 18.8%d NCT03847974 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 3.1%d NCT03847974 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 9.4%d NCT03847974 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | d other adverse event 87.5% other (not including serious) adverse events were not monitored/assessed using specific adverse even 9.4% NCT03847974 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lerodalcibep
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Lerodalcibep's landscape